
3 November 2026
EDX Medical Group plc
("EDX Medical" or the "Company")
Attending and Presenting at the Yellowstone Advisory Private Investor Evening
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, is pleased to announce that Professor Sir Christopher Evans OBE, Founder & Chief Scientific Officer of the Company, will attend and present at the Yellowstone Advisory Private Investor Evening on Wednesday 11 November 2026.
The event will be held at the London offices of SEC Newgate. Investors can register for the event here: https://www.yellowstoneadvisory.com/events
Any questions about the evening should be emailed to info@yellowstoneadvisory.com.
For enquiries, please contact:
|
Media House International |
|
|
Ramsay Smith |
+44 (0)7788 414856 ramsay@mediahouse.co.uk |
|
Gary McQueen |
+44 (0)7834 694609 gary@mediahouse.co.uk |
|
|
|
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX). The Company develops and supplies class-leading clinical diagnostics products and services.
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. The Company operates its own laboratory facilities in Cambridge UK, and has strategic product and technology partnerships with leading life sciences and healthcare organisations. Products and services are available to healthcare providers and individuals, and the Company also offers an employee health screening programme to employers.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the early detection and characterisation of disease to enable personalised treatment. Early disease detection and personal treatment optimisation is considered to be the most impactful way of improving patient outcomes.